All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Multiple myeloma (MM) is commonly described as incurable, yet patients with MM now have a very different outlook to patients 10 years ago. The advent of novel agents has seen the treatment journey transformed, with many more options now available for patients at different stages, experiencing multiple relapses. However, the concept of a cure in MM has been debated, as this depends on the chosen definition and whether that be a ‘complete cure’ or a longer period of being in a ‘disease free’ state.
Despite survival advantages with novel therapies, MM is still in general considered incurable, as patients are resigned to ongoing treatment that results in disease control, rather than a cure in its purest definition. Other malignancies, such as Hodgkin Lymphoma (HL) and Diffuse Large B Cell Lymphoma (DLBCL), are considered curable as patients can hope for a normal life-span after a short course of therapy. However, with longer survival times for MM patients, many physicians have challenged whether MM should continue to be described as incurable. In order to test the definition of a cure in MM, Praful Ravi and colleagues at the Mayo Clinic, Rochester, MN, USA, conducted a retrospective analysis of to compare the survival of young patients (< 50 years of age) with MM to the survival of young patients with follicular lymphoma (FL), HL and DLBCL. Their findings were published in Blood Cancer Journal in February 2018.
It was concluded that MM remains an incurable disease, with a cure defined as ‘treatment with subsequent complete resolution of the disease’ and the expectation that patients can hope for a normal life expectancy. However, this was a retrospective analysis, using young patients (≤ 50 years of age) treated heterogeneously. Whilst these patients, in general, are expected to have better survival outcomes, it is unknown whether young age might add a stronger genetic component and therefore more aggressive disease. Nevertheless, it was clear from this study that patients with MM in this age range had substantially worse outcomes than patients of a similar age with HL and DLBCL.
Traditionally, survival beyond 5-years was considered a cure in cancer and in this respect MM has reached that goal, but the definition has now changed, with longer treatment-free periods and indefinite survival times now the ultimate goal of a cancer cure. With current regimens, this is not yet the case for MM, but with promising cellular technologies such as CAR T-cells on the horizon, this will certainly be challenged in the near future. The more difficult goal for physicians will then be obtaining these therapies for all their patients at an affordable cost.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox